Full metadata record
DC FieldValueLanguage
dc.creatorVera, R. (R.)-
dc.creatorOtero, M.J. (M. J.)-
dc.creatorAyala-de-la-Peña, F. (F.)-
dc.creatorGonzález‑Pérez, C. (César)-
dc.creatorPeñuelas, Á. (Á.)-
dc.creatorSepúlveda, J.M. (Juan Manuel)-
dc.creatorQuer, N. (N.)-
dc.creatorDoménech‑Climent, N. (Nuria)-
dc.creatorVirizuela, J.A. (J. A.)-
dc.creatorBeorlegui, P. (P.)-
dc.creatorGorgas, M.Q (M. Q.)-
dc.date.accessioned2021-10-11T09:26:45Z-
dc.date.available2021-10-11T09:26:45Z-
dc.date.issued2019-
dc.identifier.citationVera, R. (R.); Otero, M.J. (M. J.); Ayala-de-la-Peña, F. (F.); et al. "Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients". Clinical and Translational Oncology. 21 (4), 2019, 467 - 478es
dc.identifier.issn1699-048X-
dc.identifier.otherPMID: 30298467-
dc.identifier.urihttps://hdl.handle.net/10171/62161-
dc.description.abstractAim: To define recommendations that permit safe management of antineoplastic medication, minimise medication errors and improve the safety of cancer patients undergoing treatment. Methods: By reviewing the literature and consulting the websites of various health organisations and agencies, an expert committee from the Spanish Society of Hospital Pharmacy and the Spanish Society of Medical Oncology defined a set of safe practices covering all stages of providing cancer therapy to patients. The Spanish Society of Oncology Nursing revised and endorsed the final list. Results: In total, 68 recommendations arranged in five sections were defined. They include issues concerning the training of health professionals, the technological resources needed, treatment planning, informing the patient and his/her family, the processes of prescribing, preparing, dispensing and administering cancer therapy (orally, parenterally or intrathecally), assessing patient adherence and treatment toxicity. Conclusions: It is essential for healthcare establishments to implement specific measures designed to prevent medication errors, in order to ensure the safety of cancer patients treated with antineoplastic medication.es_ES
dc.description.sponsorshipThis project was supported with unrestricted grants from SEFH and SEOM.es_ES
dc.language.isoenges_ES
dc.publisherSpringer Science and Business Media LLCes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectMaterias Investigacion::Ciencias de la Salud::Oncologíaes_ES
dc.subjectAntineoplastic agentses_ES
dc.subjectMedication errorses_ES
dc.subjectPatient safetyes_ES
dc.subjectPrevention and controles_ES
dc.subjectSafety management organisation and administrationes_ES
dc.titleRecommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.es_ES
dc.identifier.doi10.1007/s12094-018-1945-x-
dadun.citation.endingPage478es_ES
dadun.citation.number4es_ES
dadun.citation.publicationNameClinical and Translational Oncologyes_ES
dadun.citation.startingPage467es_ES
dadun.citation.volume21es_ES

Files in This Item:
Thumbnail
File
Vera2019_Article_RecommendationsByTheSpanishSoc.pdf
Description
Size
739.58 kB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.